MGFA estimates that this many people are diagnosed and living with MG in the United States, while underdiagnosis may leave the true burden higher.
Myasthenia Gravis Awareness Month 2026: Build a Reliable Response to Fluctuating Weakness
- Posted by Greg Wahlstrom, MBA, HCM
- Posted in 2026 Healthcare Observances Calendar, Health Observance Calendar
Skip to the executive brief
70,000 to 100,000
Fluctuating
Crisis risk
Control 01
Control 02
Control 03
Control 04
Control 05
Control 06
Neuromuscular Readiness Operating Brief
Myasthenia Gravis Awareness Month 2026: Build a Reliable Response to Fluctuating Weakness
Use June to strengthen rapid recognition, respiratory-risk escalation, medication safety, specialty access, treatment coordination, and the handoffs that protect people living with myasthenia gravis.
The leadership signal: fluctuating weakness demands a reliable system
June is Myasthenia Gravis Awareness Month. The Myasthenia Gravis Foundation of America reports that 2026 campaigns focus on patient and caregiver inspiration, support and education, and community action to improve understanding of this rare autoimmune neuromuscular disease. Awareness should also move hospital leaders toward a concrete operating question: will every site recognize worsening MG and respond before weakness becomes a respiratory emergency?
Myasthenia gravis, often called MG, disrupts communication between nerves and voluntary muscles. Weakness can affect the eyes, face, speech, chewing, swallowing, neck, limbs, and breathing. Symptoms often fluctuate, worsen with activity, and improve with rest. That variability can lead to missed severity when a patient appears stronger during one examination, compensates to complete a task, or deteriorates after repeated effort.
A reliable system must connect emergency medicine, neurology, respiratory therapy, nursing, pharmacy, intensive care, surgery, anesthesia, rehabilitation, case management, and outpatient care. It must also respect patient knowledge. People living with MG often recognize their own pattern, triggers, medication risks, and early warning signs before a clinician unfamiliar with the condition does.
Three facts that should shape the operating model
Weakness may change during the day and after repeated activity. One reassuring moment should not outweigh the trend, patient report, or serial assessment.
A myasthenic crisis can weaken the muscles needed to maintain the airway and breathe, creating respiratory failure that may require mechanical ventilation.
MG can resemble stroke, fatigue, medication effect, deconditioning, psychiatric illness, or other neuromuscular conditions. Common clues include drooping eyelids, double vision, nasal or slurred speech, difficulty chewing, choking, weak neck control, difficulty raising the arms, impaired walking, shortness of breath, and weakness that worsens with use. Clinical teams should avoid assuming that a normal oxygen saturation or the ability to speak briefly eliminates respiratory risk.
Diagnosis and treatment are individualized. Antibody status, disease distribution, severity, comorbidities, pregnancy, age, prior response, treatment access, and patient goals may all shape the plan. Newer targeted therapies have expanded options, including a 2025 FDA approval for certain adults and adolescents with generalized MG, but a growing treatment landscape also raises operational demands for specialist review, infusion access, monitoring, prior authorization, infection precautions, and continuity.
Build a response relay from first signal to safe transition
MG readiness should not depend on whether a clinician happens to have treated the disease before. Create one pathway that moves the patient from recognition through respiratory assessment, medication review, neurology consultation, appropriate level of care, and a discharge plan that preserves therapy and follow-up.
Recognize
Listen for fluctuating ocular, facial, bulbar, limb, neck, or breathing weakness.
Trend
Use serial clinical and respiratory assessment rather than a single snapshot.
Review
Reconcile MG therapy, recent changes, infection, procedures, and cautionary medications.
Escalate
Activate neurology, respiratory, pharmacy, and critical care at defined thresholds.
Treat
Follow the patient-specific plan and protect treatment continuity.
Transition
Carry the medication, emergency, follow-up, and access plan into the next setting.
The patient’s emergency card, medication list, specialist contact, prior crisis history, usual respiratory measures, effective treatments, and cautionary-drug information can materially improve decisions. Build a method to capture these details without forcing the patient or caregiver to repeat them at every transfer.
Six executive decisions that convert awareness into readiness
1. Standardize respiratory-risk escalation
Define who performs serial respiratory assessment, which measures and clinical signs trigger consultation, and when critical care joins the response. Include swallowing difficulty, weak cough, secretion management, fatigue, speech change, posture, and work of breathing. Avoid relying on pulse oximetry alone.
2. Put cautionary medications into workflow
MGFA identifies medications that may worsen MG, while emphasizing that risks and benefits remain patient-specific. Embed pharmacy review, order-entry warnings with useful context, medication reconciliation, and a rapid prescriber-pharmacist discussion. Avoid indiscriminate hard stops that delay necessary therapy.
3. Create a 24/7 specialty-access model
Map how emergency departments, community hospitals, and rural sites reach neurology and a higher level of care after hours. Establish transfer criteria, tele-neurology support, escalation contacts, and expected response times. The process should remain usable when beds, transport, or specialists are constrained.
4. Govern the expanding treatment pathway
Bring neurology, pharmacy, infusion, finance, utilization management, nursing, and patient access together. Review clinical eligibility, administration capacity, monitoring, infection precautions, insurance barriers, site-of-care decisions, and the risk created by interrupted treatment. Track denials and avoidable delays as operational data.
5. Make surgery and procedures MG-ready
Flag MG early in preoperative assessment. Coordinate neurology, anesthesia, surgery, pharmacy, respiratory care, and post-anesthesia monitoring. Review medications, prior crisis, bulbar or respiratory weakness, treatment timing, and postoperative disposition before the procedure begins.
6. Protect continuity after discharge
Confirm the medication supply, specialty appointment, infusion or injection schedule, home support, warning signs, emergency plan, transportation, and a contact route that works after hours. Use teach-back and include the patient’s preferred caregiver when authorized.
Design the emergency response around trajectory, not appearance
MG-related respiratory decline can be clinically complex. Patients may remain awake and interactive while respiratory muscle weakness advances. Leaders should ensure that emergency and inpatient teams know when to repeat assessment, reduce exertion, involve respiratory therapy, consult neurology, and prepare for a higher level of support.
Infection, medication exposure, treatment interruption, surgery, pregnancy, heat, stress, and other factors may worsen symptoms, but the trigger should not distract from immediate stabilization and expert assessment. The pathway must distinguish myasthenic crisis from other causes of respiratory failure while avoiding delays created by premature diagnostic certainty.
Put MG reliability on the executive scorecard
| Domain | Core measure | Executive question |
|---|---|---|
| Recognition | MG encounters with documented symptom pattern and change from baseline | Where is worsening weakness mislabeled or identified late? |
| Respiratory safety | High-risk encounters receiving serial respiratory and bulbar assessment | Are teams trending trajectory before visible crisis? |
| Medication safety | New medications reviewed for MG-specific risk and documented rationale | Are warnings useful, timely, and connected to pharmacy expertise? |
| Specialty access | Time from escalation to neurology response or transfer decision | Which sites, shifts, or patient groups wait longest? |
| Treatment continuity | Therapy starts, cycles, or refills delayed by authorization or capacity | Which operational barrier creates avoidable instability? |
| Transition reliability | Discharges with medication supply, warning signs, follow-up, and emergency plan confirmed | Can the patient act safely if weakness changes tonight? |
| Experience | Patient-reported listening, respect, coordination, and confidence in the plan | Did the system treat lived knowledge as clinical information? |
Review near misses as well as crises. A harmful medication intercepted by a pharmacist, a transfer delayed while respiratory weakness progressed, an infusion postponed by authorization, or a patient repeatedly explaining MG across departments all reveal process risk. Aggregate data should be stratified by site, geography, race and ethnicity, payer, age, and other relevant access factors to expose inequity.
A 90-day activation plan
Days 1 to 30: Map
- Name an executive sponsor and clinical-operational owner.
- Map one MG journey from emergency arrival through discharge and specialty follow-up.
- Inventory neurology, respiratory, pharmacy, critical care, transfer, infusion, and authorization capacity.
- Ask patients and caregivers where the system fails to recognize or carry forward their plan.
Days 31 to 60: Test
- Run worsening bulbar weakness, respiratory decline, cautionary-medication, procedure, and interrupted-therapy scenarios.
- Test the after-hours neurology and transfer pathway.
- Validate order-entry warnings with frontline clinicians and pharmacists.
- Audit discharge instructions, emergency planning, and follow-up access.
Days 61 to 90: Scale
- Publish the escalation standard and 24/7 contacts.
- Launch the readiness scorecard with named improvement owners.
- Integrate MG scenarios into emergency, nursing, pharmacy, anesthesia, and respiratory competencies.
- Continue quarterly review after Awareness Month ends.
Conclusion: reliability begins before crisis
Myasthenia Gravis Awareness Month 2026 offers a clear executive mandate. A rare diagnosis cannot be an excuse for an unreliable response. Health systems must recognize fluctuating weakness, trend respiratory and bulbar risk, bring specialist and pharmacy expertise into decisions, protect treatment continuity, and listen to patients who know their own pattern.
The practical standard is simple: recognize the signal, repeat the assessment, review medications, escalate early, coordinate treatment, and carry the plan forward. When leaders turn those actions into a dependable relay, they reduce preventable delay and create safer care for every person living with MG.
Authoritative resources
2026 campaign and MG information
Emergency, medication, and treatment readiness
Clinical note: New or worsening breathing difficulty, swallowing weakness, or rapidly progressing symptoms may require emergency evaluation. Medication and treatment decisions are individualized. Practice note: This executive brief supports operational readiness and does not replace patient-specific clinical judgment, prescribing information, current guidelines, accreditation requirements, or organizational counsel.
